NASDAQ-GS · traded in Congress
Regeneron Pharmaceuticals, REGN
$943.9017 +39.5517 (+4.37%) Nov 9, 2026 4:01 AM ET
Market value$97.6B
P/E ratio-
Analyst target$923.50
52-week range-
Avg volume768,496
Dividend yield0.42%
Chart
Analyst ratings
- 20 buy
- 9 hold
- 1 sell
Low target$795.00
Average target$974.58
High target$1,175.00
Quarterly financials
| Quarter ended | Revenue | Gross profit | Net income | Net margin |
|---|---|---|---|---|
| $5,116M | - | $1,949M | 38.1% | |
| $4,291M | - | $1,297M | 30.2% | |
| $3,605M | - | $727M | 20.2% | |
| $3,884M | - | $845M | 21.7% |
Congress trades in REGN
Members of Congress disclosed 2 transactions in REGN in the filings we have processed.
| Traded | Member | Type | Amount | Filed |
|---|---|---|---|---|
| 05/15/2026 | Gilbert Cisneros CA31 | Sale | $1,001 - $15,000 | 6/8/2026 filing |
| 02/12/2026 | Julia Letlow LA05 | Purchase | $1,001 - $15,000 | 3/12/2026 filing |
Disclosed under the STOCK Act. Amounts are the ranges the law requires, filings can lag a trade by up to 45 days, and a disclosure is not evidence of wrongdoing. All congressional trades ›
Other companies
Price and key figures from Nasdaq's public quote data, refreshed through the day; the chart is live from TradingView; options activity, ratings, financials, earnings and filings refreshed through the day. Congressional trades parsed from official House filings. Market information, not investment advice.
